StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.

CGEN has been the subject of a number of other research reports. JMP Securities reduced their target price on Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a report on Monday, August 8th. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Truist Financial cut their price objective on Compugen from $14.00 to $4.00 and set a buy rating for the company in a report on Tuesday, August 23rd. Finally, Oppenheimer cut their price objective on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Compugen currently has a consensus rating of Moderate Buy and an average price target of $6.20.

Compugen Stock Performance

Shares of NASDAQ:CGEN opened at $0.91 on Tuesday. The stock has a fifty day moving average of $1.41 and a 200-day moving average of $2.04. The company has a market capitalization of $79.02 million, a PE ratio of -2.34 and a beta of 2.15. Compugen has a one year low of $0.91 and a one year high of $7.48.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in shares of Compugen by 1.9% in the first quarter. Taylor Frigon Capital Management LLC now owns 672,055 shares of the biotechnology company's stock valued at $2,164,000 after purchasing an additional 12,769 shares in the last quarter. Eagle Rock Investment Company LLC acquired a new stake in Compugen during the 4th quarter worth $83,000. Qube Research & Technologies Ltd acquired a new stake in Compugen during the 1st quarter worth $85,000. WMS Partners LLC acquired a new stake in Compugen during the 1st quarter worth $74,000. Finally, Antonetti Capital Management LLC grew its holdings in Compugen by 41.5% during the 1st quarter. Antonetti Capital Management LLC now owns 350,671 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 102,771 shares during the period.

About Compugen

(Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

See Also

• Get a free copy of the StockNews.com research report on Compugen (CGEN)
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• Is Ford Rolling To A Rebound After Its Q3 Warning
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Has AMD stock stock fallen too far?

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.